Cargando…
Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy
BACKGROUND: Recently, we described a novel autoantibody, anti-Sj/ITPR1-IgG, that targets the inositol 1,4,5-trisphosphate receptor type 1 (ITPR1) in patients with cerebellar ataxia. However, ITPR1 is expressed not only by Purkinje cells but also in the anterior horn of the spinal cord, in the substa...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078930/ https://www.ncbi.nlm.nih.gov/pubmed/27776522 http://dx.doi.org/10.1186/s12974-016-0737-x |
_version_ | 1782462480733175808 |
---|---|
author | Jarius, Sven Ringelstein, Marius Haas, Jürgen Serysheva, Irina I. Komorowski, Lars Fechner, Kai Wandinger, Klaus-Peter Albrecht, Philipp Hefter, Harald Moser, Andreas Neuen-Jacob, Eva Hartung, Hans-Peter Wildemann, Brigitte Aktas, Orhan |
author_facet | Jarius, Sven Ringelstein, Marius Haas, Jürgen Serysheva, Irina I. Komorowski, Lars Fechner, Kai Wandinger, Klaus-Peter Albrecht, Philipp Hefter, Harald Moser, Andreas Neuen-Jacob, Eva Hartung, Hans-Peter Wildemann, Brigitte Aktas, Orhan |
author_sort | Jarius, Sven |
collection | PubMed |
description | BACKGROUND: Recently, we described a novel autoantibody, anti-Sj/ITPR1-IgG, that targets the inositol 1,4,5-trisphosphate receptor type 1 (ITPR1) in patients with cerebellar ataxia. However, ITPR1 is expressed not only by Purkinje cells but also in the anterior horn of the spinal cord, in the substantia gelatinosa and in the motor, sensory (including the dorsal root ganglia) and autonomic peripheral nervous system, suggesting that the clinical spectrum associated with autoimmunity to ITPR1 may be broader than initially thought. Here we report on serum autoantibodies to ITPR1 (up to 1:15,000) in three patients with (radiculo)polyneuropathy, which in two cases was associated with cancer (ITPR1-expressing adenocarcinoma of the lung, multiple myeloma), suggesting a paraneoplastic aetiology. METHODS: Serological and other immunological studies, and retrospective analysis of patient records. RESULTS: The clinical findings comprised motor, sensory (including severe pain) and autonomic symptoms. While one patient presented with subacute symptoms mimicking Guillain-Barré syndrome (GBS), the symptoms progressed slowly in two other patients. Electrophysiology revealed delayed F waves; a decrease in motor and sensory action potentials and conduction velocities; delayed motor latencies; signs of denervation, indicating sensorimotor radiculopolyneuropathy of the mixed type; and no conduction blocks. ITPR1-IgG belonged to the complement-activating IgG1 subclass in the severely affected patient but exclusively to the IgG2 subclass in the two more mildly affected patients. Cerebrospinal fluid ITPR1-IgG was found to be of predominantly extrathecal origin. A (3)H-thymidine-based proliferation assay confirmed the presence of ITPR1-reactive lymphocytes among peripheral blood mononuclear cells (PBMCs). Immunophenotypic profiling of PBMCs protein demonstrated predominant proliferation of B cells, CD4 T cells and CD8 memory T cells following stimulation with purified ITPR1 protein. Patient ITPR1-IgG bound both to peripheral nervous tissue and to lung tumour tissue. A nerve biopsy showed lymphocyte infiltration (including cytotoxic CD8 cells), oedema, marked axonal loss and myelin-positive macrophages, indicating florid inflammation. ITPR1-IgG serum titres declined following tumour removal, paralleled by clinical stabilization. CONCLUSIONS: Our findings expand the spectrum of clinical syndromes associated with ITPR1-IgG and suggest that autoimmunity to ITPR1 may underlie peripheral nervous system diseases (including GBS) in some patients and may be of paraneoplastic origin in a subset of cases. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12974-016-0737-x) contains supplementary material. |
format | Online Article Text |
id | pubmed-5078930 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-50789302016-10-31 Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy Jarius, Sven Ringelstein, Marius Haas, Jürgen Serysheva, Irina I. Komorowski, Lars Fechner, Kai Wandinger, Klaus-Peter Albrecht, Philipp Hefter, Harald Moser, Andreas Neuen-Jacob, Eva Hartung, Hans-Peter Wildemann, Brigitte Aktas, Orhan J Neuroinflammation Research BACKGROUND: Recently, we described a novel autoantibody, anti-Sj/ITPR1-IgG, that targets the inositol 1,4,5-trisphosphate receptor type 1 (ITPR1) in patients with cerebellar ataxia. However, ITPR1 is expressed not only by Purkinje cells but also in the anterior horn of the spinal cord, in the substantia gelatinosa and in the motor, sensory (including the dorsal root ganglia) and autonomic peripheral nervous system, suggesting that the clinical spectrum associated with autoimmunity to ITPR1 may be broader than initially thought. Here we report on serum autoantibodies to ITPR1 (up to 1:15,000) in three patients with (radiculo)polyneuropathy, which in two cases was associated with cancer (ITPR1-expressing adenocarcinoma of the lung, multiple myeloma), suggesting a paraneoplastic aetiology. METHODS: Serological and other immunological studies, and retrospective analysis of patient records. RESULTS: The clinical findings comprised motor, sensory (including severe pain) and autonomic symptoms. While one patient presented with subacute symptoms mimicking Guillain-Barré syndrome (GBS), the symptoms progressed slowly in two other patients. Electrophysiology revealed delayed F waves; a decrease in motor and sensory action potentials and conduction velocities; delayed motor latencies; signs of denervation, indicating sensorimotor radiculopolyneuropathy of the mixed type; and no conduction blocks. ITPR1-IgG belonged to the complement-activating IgG1 subclass in the severely affected patient but exclusively to the IgG2 subclass in the two more mildly affected patients. Cerebrospinal fluid ITPR1-IgG was found to be of predominantly extrathecal origin. A (3)H-thymidine-based proliferation assay confirmed the presence of ITPR1-reactive lymphocytes among peripheral blood mononuclear cells (PBMCs). Immunophenotypic profiling of PBMCs protein demonstrated predominant proliferation of B cells, CD4 T cells and CD8 memory T cells following stimulation with purified ITPR1 protein. Patient ITPR1-IgG bound both to peripheral nervous tissue and to lung tumour tissue. A nerve biopsy showed lymphocyte infiltration (including cytotoxic CD8 cells), oedema, marked axonal loss and myelin-positive macrophages, indicating florid inflammation. ITPR1-IgG serum titres declined following tumour removal, paralleled by clinical stabilization. CONCLUSIONS: Our findings expand the spectrum of clinical syndromes associated with ITPR1-IgG and suggest that autoimmunity to ITPR1 may underlie peripheral nervous system diseases (including GBS) in some patients and may be of paraneoplastic origin in a subset of cases. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12974-016-0737-x) contains supplementary material. BioMed Central 2016-10-24 /pmc/articles/PMC5078930/ /pubmed/27776522 http://dx.doi.org/10.1186/s12974-016-0737-x Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Jarius, Sven Ringelstein, Marius Haas, Jürgen Serysheva, Irina I. Komorowski, Lars Fechner, Kai Wandinger, Klaus-Peter Albrecht, Philipp Hefter, Harald Moser, Andreas Neuen-Jacob, Eva Hartung, Hans-Peter Wildemann, Brigitte Aktas, Orhan Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy |
title | Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy |
title_full | Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy |
title_fullStr | Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy |
title_full_unstemmed | Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy |
title_short | Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy |
title_sort | inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078930/ https://www.ncbi.nlm.nih.gov/pubmed/27776522 http://dx.doi.org/10.1186/s12974-016-0737-x |
work_keys_str_mv | AT jariussven inositol145trisphosphatereceptortype1autoantibodiesinparaneoplasticandnonparaneoplasticperipheralneuropathy AT ringelsteinmarius inositol145trisphosphatereceptortype1autoantibodiesinparaneoplasticandnonparaneoplasticperipheralneuropathy AT haasjurgen inositol145trisphosphatereceptortype1autoantibodiesinparaneoplasticandnonparaneoplasticperipheralneuropathy AT seryshevairinai inositol145trisphosphatereceptortype1autoantibodiesinparaneoplasticandnonparaneoplasticperipheralneuropathy AT komorowskilars inositol145trisphosphatereceptortype1autoantibodiesinparaneoplasticandnonparaneoplasticperipheralneuropathy AT fechnerkai inositol145trisphosphatereceptortype1autoantibodiesinparaneoplasticandnonparaneoplasticperipheralneuropathy AT wandingerklauspeter inositol145trisphosphatereceptortype1autoantibodiesinparaneoplasticandnonparaneoplasticperipheralneuropathy AT albrechtphilipp inositol145trisphosphatereceptortype1autoantibodiesinparaneoplasticandnonparaneoplasticperipheralneuropathy AT hefterharald inositol145trisphosphatereceptortype1autoantibodiesinparaneoplasticandnonparaneoplasticperipheralneuropathy AT moserandreas inositol145trisphosphatereceptortype1autoantibodiesinparaneoplasticandnonparaneoplasticperipheralneuropathy AT neuenjacobeva inositol145trisphosphatereceptortype1autoantibodiesinparaneoplasticandnonparaneoplasticperipheralneuropathy AT hartunghanspeter inositol145trisphosphatereceptortype1autoantibodiesinparaneoplasticandnonparaneoplasticperipheralneuropathy AT wildemannbrigitte inositol145trisphosphatereceptortype1autoantibodiesinparaneoplasticandnonparaneoplasticperipheralneuropathy AT aktasorhan inositol145trisphosphatereceptortype1autoantibodiesinparaneoplasticandnonparaneoplasticperipheralneuropathy |